Ogsiveo
What Ogsiveo is used for
Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Ogsiveo
- Active substance
- nirogacestat
- Disease area
- Desmoid Tumors
- Medicine group
- Other antineoplastic agents
- ATC code
- L01XX81
- Marketing authorisation holder
- Merck Europe B.V.
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ogsiveo used for?
Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.
What is the active substance in Ogsiveo?
Ogsiveo contains nirogacestat.
Who makes Ogsiveo?
The EU marketing authorisation holder is Merck Europe B.V..
Is Ogsiveo an orphan medicine?
Yes. Ogsiveo is designated an orphan medicine in the EU, for a rare disease (Desmoid Tumors).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU